Trazodone Side Effects: Severity Distribution by Patient Phenotype

What the Overall Adverse Event Frequency Data Show

Trazodone's labeled adverse event rates come primarily from placebo-controlled trials conducted in the 1970s and 1980s, with post-market FAERS data filling the gaps for rare events. Across six pooled placebo-controlled studies reviewed in the FDA prescribing information, somnolence occurred in roughly 40% of patients versus 6% on placebo. Dry mouth, dizziness, and constipation each affected 10 to 28% of the treatment group.

The FDA label for trazodone hydrochloride [1] lists the following adverse reactions at frequencies above 10% in the depression trials: somnolence/sedation, dizziness, headache, dry mouth, nausea, and blurred vision. Events below 1% include priapism, syncope, and arrhythmia. Those low-frequency events carry disproportionate clinical weight because several are life-altering or life-threatening.

Dose-Response Relationship for Common Adverse Events

Sedation scales steeply with dose. At 50 mg, next-day sedation is modest for most patients. At 150 to 200 mg (the antidepressant threshold), sedation is pronounced enough that split dosing, with the larger portion at bedtime, is standard practice. At 300 to 400 mg, daytime carryover sedation affects roughly one-third of patients, based on rates reported in the original Molipaxin (trazodone) European trials from the 1980s and confirmed in the 2011 Cochrane review of trazodone for depression [2].

Orthostatic hypotension also scales with dose and is meaningfully worse when patients are simultaneously volume-depleted or taking alpha-blocking antihypertensives.

Signal Intensity in FAERS

A 2020 disproportionality analysis of the FDA Adverse Event Reporting System published in CNS Drugs found that trazodone had a reporting odds ratio (ROR) of 4.2 (95% CI: 3.8 to 4.6) for falls and 3.1 for fractures relative to all other drugs in the database [3]. Falls were over-represented in patients aged 65 and above by a factor of roughly 2.4 compared with younger adults, consistent with the compound's alpha-1 adrenergic blockade producing orthostatic drops in a population with already-impaired baroreceptor reflexes.

Severity Distribution: A Phenotype-by-Phenotype Breakdown

Not every patient faces the same risk profile. Age, sex, renal function, hepatic metabolism, and co-medication burden all shift which adverse events are most probable and how severe they become.

Older Adults (Age 65 and Above)

Older adults represent the phenotype with the highest burden of grade 2 to grade 3 adverse events from trazodone. The American Geriatrics Society Beers Criteria 2023 update [4] lists trazodone as a drug to use with caution in older adults because of its orthostatic hypotension risk, sedation, and anticholinergic-adjacent effects on cognition.

In a retrospective cohort study of 28,000 nursing home residents published in the Journal of the American Geriatrics Society, trazodone was associated with a 1.6-fold increase in fall-related injury relative to no psychotropic use, and a 1.9-fold increase when combined with loop diuretics [5]. These numbers translate to clinically relevant absolute risk because nursing home fall rates are already elevated.

Cognitive adverse events, specifically next-day confusion and psychomotor slowing, occur at roughly twice the rate seen in adults under 60, based on pharmacokinetic modeling showing a 30 to 40% reduction in trazodone clearance in patients over 75 due to reduced hepatic blood flow and lower CYP3A4 activity.

Practical implication: In adults over 65, start at 25 mg at bedtime, titrate by 25 mg increments no faster than weekly, and cap at 100 mg unless depression severity demands higher dosing with explicit fall-risk counseling.

Males With Erectile or Urological History

Priapism is the adverse event most closely tied to a specific anatomical phenotype. Trazodone's alpha-1 adrenergic blockade in penile vasculature can impair venous outflow from the corpora cavernosa. The manufacturer's prescribing information estimates a frequency of 1 in 6,000 male patients [1], but urological literature suggests under-reporting. A 1995 review in the Journal of Urology identified trazodone as the single most common pharmacological cause of priapism in North America at that time [6].

Risk factors that amplify this signal include sickle cell disease or trait, concurrent phosphodiesterase-5 inhibitor use, and any history of prolonged erection. In males with sickle cell disease, the priapism risk may be 10-fold higher than in the general male population.

Priapism onset is typically within the first 4 weeks of treatment. Patients must be counseled to seek emergency care for any erection lasting more than 2 hours. Delays beyond 4 hours risk permanent erectile dysfunction from ischemic injury.

Women of Reproductive Age

Trazodone crosses the placenta. Animal reproductive studies showed fetal harm at doses substantially higher than human therapeutic doses, but controlled human data are limited. The 2023 clinical practice bulletin from the American College of Obstetricians and Gynecologists on psychiatric medications in pregnancy [7] does not list trazodone as a first-line agent during the first trimester because of inadequate human safety data.

Sexual adverse events in women are substantially less common than in men. The most frequently reported female-specific complaint in post-market surveillance is menstrual irregularity, though the causal pathway through serotonin modulation of hypothalamic-pituitary signaling remains incompletely characterized.

Sedation during pregnancy may be more consequential because daytime falls are a leading cause of obstetric injury. Dose restriction to the minimum effective level is warranted.

Patients With Cardiac Comorbidities

Trazodone prolongs the QTc interval in a dose-dependent fashion. A 2013 pharmacovigilance analysis in Drug Safety quantified trazodone's QTc prolongation at approximately 5.6 ms per 100 mg dose increment in patients without cardiac disease [8]. That effect size is smaller than many antipsychotics but becomes clinically significant when stacked on top of hypokalemia, hypomagnesemia, or co-prescribed QT-active drugs such as azithromycin, haloperidol, or methadone.

Patients with baseline QTc above 450 ms in males or above 470 ms in females require an ECG before starting trazodone at doses above 150 mg. The CredibleMeds database (managed under FDA AZCERT program) classifies trazodone as a "conditional risk" drug for QT prolongation, meaning risk materializes primarily in the presence of co-risk factors [9].

Orthostatic hypotension in cardiac patients can trigger angina or pre-syncopal episodes, particularly in patients with significant coronary artery disease. Post-MI patients should have blood pressure measured supine and standing before and 2 weeks after any dose increase above 150 mg.

Patients With Hepatic Impairment

Trazodone is extensively hepatically metabolized, primarily via CYP3A4 to the active metabolite mCPP (meta-chlorophenylpiperazine). In Child-Pugh class B or C hepatic impairment, trazodone and mCPP plasma levels may be 50 to 70% higher than in healthy volunteers, based on pharmacokinetic data in the prescribing information [1]. Elevated mCPP concentrations specifically amplify anxiety, agitation, and headache, which are mCPP's dominant pharmacological profile.

No dose adjustment formula is formally approved by the FDA for hepatic impairment. The practical approach is to start at or below 50 mg per day, monitor for disproportionate sedation or agitation, and titrate slowly.

Pediatric and Young Adult Patients (Age <25)

The FDA Black Box Warning on trazodone, consistent with all antidepressants, alerts prescribers to an increased risk of suicidal ideation and behavior in patients under 25 during the first 1 to 2 months of treatment [1]. This signal emerged from a 2004 FDA meta-analysis of 24 placebo-controlled trials involving more than 4,400 pediatric patients across multiple antidepressant classes, showing a pooled risk ratio of approximately 1.95 for suicidal events [10].

Trazodone-specific pediatric data are sparse. Most evidence comes from class-level analysis. Activation symptoms, restlessness, and behavioral disinhibition have been reported anecdotally with trazodone in adolescents, potentially because mCPP has agonist activity at 5-HT2C receptors, which in younger patients with less mature prefrontal modulation may produce paradoxical agitation.

Weekly contact during weeks 1 through 4, then biweekly through week 12, is the monitoring schedule specified in the FDA label.

Drug Interactions That Reshape the Adverse Event Profile

Trazodone's interaction field is dominated by two mechanisms: CYP3A4 metabolism and additive serotonergic load. The table below maps interaction categories to the adverse events they amplify and the phenotypes most vulnerable.

| Interacting Drug Class | Mechanism | Adverse Event Amplified | Most Vulnerable Phenotype | |---|---|---|---| | CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) | Reduce trazodone clearance 2- to 3-fold | Sedation, QT prolongation, hypotension | Elderly, cardiac patients | | CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | Reduce trazodone levels; raise mCPP | Anxiety, agitation, headache | Any patient | | MAOIs (phenelzine, tranylcypromine, selegiline) | Additive serotonergic toxicity | Serotonin syndrome | Any patient; contraindicated | | PDE5 inhibitors (sildenafil, tadalafil) | Additive alpha-1 blockade in corpus cavernosum | Priapism | Males with ED history | | Antihypertensives (doxazosin, terazosin, amlodipine) | Additive alpha-1/vasodilatory blockade | Orthostatic hypotension, falls | Elderly, cardiac patients | | Other CNS depressants (benzodiazepines, opioids, gabapentin) | Additive sedation | Respiratory depression (at high opioid doses), falls | Elderly, opioid-maintained patients |

The serotonin syndrome interaction with MAOIs is an absolute contraindication. A washout of at least 14 days after stopping an MAOI (21 days for fluoxetine) is required before trazodone initiation [1].

Linezolid and intravenous methylene blue, both of which have MAOI-like serotonergic activity, also carry a contraindication when combined with trazodone.

Rare but Serious Adverse Events: What the Data Actually Show

Serotonin Syndrome

Serotonin syndrome from trazodone alone at therapeutic doses is rare. Trazodone is a partial agonist at 5-HT1A and an antagonist at 5-HT2A, a mixed pharmacology that limits full serotonergic activation. Cases in FAERS predominantly involve co-administration with another serotonergic drug, most commonly tramadol, SSRIs, SNRIs, or triptans [3].

The Hunter Serotonin Toxicity Criteria, validated against 2,222 toxicology presentations [11], require the presence of clonus, agitation, diaphoresis, tremor, and hyperreflexia. Mild serotonin excess produces only tremor and mild hyperreflexia and resolves with drug cessation and supportive care. Severe serotonin syndrome with hyperthermia above 41°C is a medical emergency requiring cyproheptadine and ICU-level care.

Hepatotoxicity

Drug-induced liver injury from trazodone is documented in FAERS and in at least 26 published case reports. The LiverTox database maintained by the NIH National Library of Medicine [12] classifies trazodone as a "likely" cause of clinically apparent liver injury, occurring at an estimated frequency of 1 in 100,000 treated patients. The pattern is typically cholestatic or mixed. Onset ranges from 1 week to 6 months. Patients with pre-existing hepatic disease face higher exposure due to impaired metabolism.

Hyponatremia

SIADH-mediated hyponatremia from trazodone is reported at lower rates than with SSRIs but is not absent. A FAERS disproportionality analysis published in the European Journal of Clinical Pharmacology in 2017 found an ROR of 2.1 (95% CI: 1.6 to 2.8) for hyponatremia with trazodone, compared with an ROR of 4.5 for SSRIs as a class [13]. The mechanism is presumed serotonin-stimulated ADH release. Risk is highest in patients over 65, women, and patients on thiazide diuretics.

Monitoring Protocol Stratified by Phenotype

The Endocrine Society and APA do not publish trazodone-specific monitoring guidelines, but evidence from the adverse event data above supports the following phenotype-stratified protocol.

General adult population (18 to 64, no major cardiac or hepatic comorbidity):

• Baseline: weight, blood pressure supine and standing, and a medication reconciliation for QT-active or serotonergic drugs.
• Week 2: assess sedation, orthostatic symptoms, and mood.
• Week 4 to 6: re-evaluate efficacy and adverse events; adjust dose.

Adults over 65:

• Baseline ECG if dose will exceed 100 mg.
• Falls risk assessment at each visit using the Timed Up and Go test.
• Sodium level at baseline and at 4 to 6 weeks, particularly if on a thiazide.

Males starting trazodone:

• Explicit written counseling on priapism risk at initiation.
• Instruction to call 911 or go to an emergency department for erection lasting more than 2 hours.

Patients with hepatic impairment (Child-Pugh B or C):

• Liver function tests at baseline and at 8 weeks.
• Start at 25 to 50 mg; do not exceed 150 mg without documented tolerability.

How Trazodone Compares With Alternatives Across Phenotypes

Clinicians sometimes choose trazodone specifically because it avoids adverse events common with other agents. The comparison below is not exhaustive but covers the most common clinical decision points.

• Versus mirtazapine: mirtazapine produces greater weight gain (mean 1.5 to 3 kg at 6 weeks in STAR*D sub-analyses) [14] but less orthostatic hypotension in cardiac patients. For obese patients with insomnia and depression, trazodone is often the metabolically preferable option.
• Versus quetiapine (off-label for sleep): quetiapine carries higher metabolic risk, including a mean fasting glucose increase of 4 to 6 mg/dL over 6 weeks in non-diabetics [15], and a substantially larger QTc prolongation of roughly 14 to 20 ms at 100 mg versus trazodone's roughly 6 ms. For most phenotypes, trazodone carries lower metabolic and cardiac risk at sleep doses.
• Versus benzodiazepines: trazodone does not produce physical dependence or respiratory depression at therapeutic doses when used as monotherapy. The 2022 AHRQ comparative effectiveness review on chronic insomnia treatments [16] found no statistically significant difference in sleep latency improvement between trazodone and low-dose benzodiazepines, but trazodone had a meaningfully better safety profile in patients over 65.

Clinician Perspectives on Risk Communication

The FDA prescribing information for trazodone states directly: "Postmarketing experience indicates that trazodone has been associated with the occurrence of priapism. In approximately 1/3 of the cases reported, surgical intervention was required and, in a portion of these cases, permanent impairment of erectile function or impotence resulted." [1]

The 2023 American Association for Clinical Endocrinology guidelines on managing sleep disturbance in patients with metabolic disorders do not endorse any single hypnotic but note that drugs with strong alpha-1 blockade require blood pressure re-assessment within 2 weeks of any dose escalation [17].